Regulation - Regulation, Health Medical Pharma

Filter

Popular Filters

Actavis and Forest to divest four generics to gain FTC OK for merger

01-07-2014

In order for Ireland-headquartered generics major Actavis to complete its previously-announced $25 billion…

ActavisForest LaboratoriesGeneric pharmaceuticalsGenericsHealth Medical PharmaMedicinePharmaceutical industryPharmacologyRegulationUSA

Actavis files for generic version of Acorda’s Ampyra

Actavis files for generic version of Acorda’s Ampyra

27-06-2014

US biotech firm Acorda Therapeutics has been advised that Ireland-headquartered generics major Actavis…

Acorda TherapeuticsActavisAmpyraGenericsHealth Medical PharmaMedicinePharmaceutical sciencesPharmacologyRegulationUS Food and Drug AdministrationUSA

Ranbaxy’s Ohm receives FDA approval for generic of Novartis’ Diovan

Ranbaxy’s Ohm receives FDA approval for generic of Novartis’ Diovan

27-06-2014

Ohm Laboratories, a wholly owned subsidiary of India’s largest drugmaker Ranbaxy Laboratories, has…

Angiotensin II receptor antagonistsCardio-vascularChemistryDiovanGenericsHealth Medical PharmaHealth Medical PharmaNovartisOrganic chemistryRanbaxy LaboratoriesRegulationUSA

Vertex leaps on positive Ph III results with lumacaftor

Vertex leaps on positive Ph III results with lumacaftor

24-06-2014

US biotech firm Vertex Pharmaceuticals saw its share price rocket nearly 52% to $101.20 in extending…

BiotechnologyBusiness FinanceCystic fibrosisHealth Medical PharmaKalydecolumacaftorMedicinePhenolsRare diseasesRegulationResearchVertex Pharmaceuticals

Orexigen stock falls after FDA extends review of obesity drug

Orexigen stock falls after FDA extends review of obesity drug

11-06-2014

Obesity-focused US biopharmaceutical company Orexigen Therapeutics says that the US Food and Drug Administration…

AnorecticsBiopharmaceuticalCardio-vascularContraveHealth Medical PharmaNB32Orexigen TherapeuticsPharmaceuticalPharmacologyRegulationUSA

US FDA approves Eisai’s Aloxi for children and extends exclusivity

US FDA approves Eisai’s Aloxi for children and extends exclusivity

29-05-2014

Japanese drug major Eisai announced today that the antiemetic agent Aloxi (palonosetron HCI) has been…

AloxiAntiemeticsEisaiHealth Medical PharmaJapanMedicineOncologyPharmaceuticalRegulationUnited StatesUSAVomiting

Wockhardt target for fresh FDA concerns over US unit

Wockhardt target for fresh FDA concerns over US unit

28-05-2014

Indian drugmaker Wockhardt is facing fresh concerns from the US Food and Drug Administration over processes…

Clinical researchHealth Medical PharmaIndiaManaging directorPharmaceuticalPharmaceutical sciencesProductionRegulationUnited StatesUSAWockhardt

GPs lack awareness of NICE guidelines on HMB, survey shows

GPs lack awareness of NICE guidelines on HMB, survey shows

09-05-2014

Less than 5% of UK general practitioners (GPs) prescribe in line with guidelines from the National Institute…

BayerHealth Medical PharmaHealth Medical PharmaMilitary scienceNavigationPharmaceuticalRegulationSocial IssuesUKWomen's Health

Boehringer Ingelheim’s volasertib granted orphan drug designation for AML

Boehringer Ingelheim’s volasertib granted orphan drug designation for AML

17-04-2014

The US Food and Drug Administration and the European Commission have granted German family-owned drug…

Boehringer IngelheimEuropeGermanyHealth Medical PharmaMajorMedicineOncologyPharmaceuticalPharmacologyRegulationUS Food and Drug AdministrationUSAvolasertib

NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

15-04-2014

In final draft guidance published today, the UK’s National Institute for Health and Care Excellence…

AnatomyCare ExcellenceFerring PharmaceuticalsFirmagonHealth Medical PharmaMedicineOncologyPharmaceuticalRegulationUKUnited Kingdom

Back to top